Medical Media Systems has purchased the assets of GHRL, a Cambridge, MA, provider of validated industry-standard technology for 3D imaging of tumors. As part of the purchasing agreement, the West Lebanon, NH, provider of remote 3D medical imaging and
Medical Media Systems has purchased the assets of GHRL, a Cambridge, MA, provider of validated industry-standard technology for 3D imaging of tumors. As part of the purchasing agreement, the West Lebanon, NH, provider of remote 3D medical imaging and treatment planning applications will also sponsor a National Cancer Institute-funded clinical study to examine whether tumor volume is a better indicator of changes in tumor size and growth than the 2D-based RECIST (response evaluation criteria in solid tumors) protocol that measures the longest diameters of target lesions. The retrospective study, scheduled to begin in early 2004, will be conducted with the Dana Farber Cancer Institute and Harvard Medical School-affiliated hospitals.
Study Shows No Impact of Hormone Therapy on PET/CT with 18F-Piflufolastat in PCa Imaging
May 7th 2025For patients with recurrent or metastatic prostate cancer, new research findings showed no significant difference in the sensitivity of 18F-piflufolastat PET/CT between patients on concurrent hormone therapy and those without hormone therapy.